{"id":"amg-334-dose-1","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site reactions"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL2109249","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to the CGRP receptor, AMG 334 prevents the action of CGRP, a neuropeptide involved in the transmission of pain signals. This mechanism of action is thought to be beneficial in the treatment of migraine. The exact molecular target of AMG 334 is the CGRP receptor, which is a G protein-coupled receptor.","oneSentence":"AMG 334 is a fully human monoclonal antibody that targets and inhibits the activity of the calcitonin gene-related peptide (CGRP) receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:08:40.909Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Migraine prevention"}]},"trialDetails":[{"nctId":"NCT03832998","phase":"PHASE3","title":"Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine","status":"COMPLETED","sponsor":"Amgen","startDate":"2019-09-05","conditions":"Migraine","enrollment":284},{"nctId":"NCT03836040","phase":"PHASE3","title":"Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2019-07-19","conditions":"Migraine","enrollment":457},{"nctId":"NCT03499119","phase":"PHASE1","title":"AMG 334 20160172 Pediatric Migraine PK Study.","status":"COMPLETED","sponsor":"Amgen","startDate":"2018-05-04","conditions":"Migraine","enrollment":53},{"nctId":"NCT01952574","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-08-06","conditions":"Migraine","enrollment":483},{"nctId":"NCT02630459","phase":"PHASE2","title":"A Safety and Efficacy Study to Evaluate AMG 334 in Migraine Prevention","status":"COMPLETED","sponsor":"Amgen","startDate":"2016-01-06","conditions":"Migraine","enrollment":475},{"nctId":"NCT02456740","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-07-17","conditions":"Migraine","enrollment":955},{"nctId":"NCT02542605","phase":"PHASE1","title":"To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-11-11","conditions":"Migraine","enrollment":35},{"nctId":"NCT02741310","phase":"PHASE1","title":"Study to Evaluate the Effect of Erenumab on Blood Pressure When Given Concomitantly With Subcutaneous Sumatriptan","status":"COMPLETED","sponsor":"Amgen","startDate":"2016-02-22","conditions":"Healthy Subjects","enrollment":34},{"nctId":"NCT01723514","phase":"PHASE1","title":"Ascending Multiple-Doses of Erenumab (AMG 334) in Healthy Adults and in Migraine Patients","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-11-14","conditions":"Migraine","enrollment":48},{"nctId":"NCT01688739","phase":"PHASE1","title":"Ascending Single Doses of Erenumab (AMG 334) in Healthy Adults and Migraine Patients","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-03-13","conditions":"Migraine","enrollment":61},{"nctId":"NCT02792517","phase":"PHASE1","title":"Erenumab (AMG 334) Plus Combined Oral Contraceptive Drug Interaction Study in Healthy Females","status":"COMPLETED","sponsor":"Amgen","startDate":"2016-02-12","conditions":"Headache, Migraine","enrollment":41},{"nctId":"NCT02575833","phase":"PHASE2","title":"Treadmill Cardiovascular Safety Study of Erenumab (AMG 334)","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-11-23","conditions":"Stable Angina","enrollment":89}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Erenumab"],"phase":"phase_2","status":"active","brandName":"AMG 334 Dose 1","genericName":"AMG 334 Dose 1","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AMG 334 is a fully human monoclonal antibody that targets and inhibits the activity of the calcitonin gene-related peptide (CGRP) receptor. Used for Migraine prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}